Profile data is unavailable for this security.
About the company
Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
- Revenue in CNY (TTM)2.95bn
- Net income in CNY580.86m
- Incorporated1998
- Employees4.48k
- LocationGan & Lee PharmaceuticalsRoom 1805, 18F, Tower COriental Media, No. 4, Guanghua RoadChaoyang DistrictBEIJING 101109ChinaCHN
- Phone+86 1 080593699
- Fax+86 1 080593678
- Websitehttps://www.ganlee.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing King-Frind Bchmcl Phrmctcl C Ltd | 3.88bn | -422.97m | 24.06bn | 1.45k | -- | 3.84 | -- | 6.20 | -0.3269 | -0.3269 | 2.43 | 3.88 | 0.3774 | 0.5012 | 4.35 | 2,672,280.00 | -4.12 | 8.97 | -5.76 | 13.15 | 41.00 | 45.59 | -10.91 | 20.12 | 1.51 | -2.96 | 0.269 | 26.33 | 5.89 | 18.25 | -117.37 | -- | 38.32 | 13.75 |
| Shanghai Junshi Biosciences Co Ltd | 1.79bn | -1.80bn | 25.67bn | 2.53k | -- | 4.80 | -- | 14.36 | -1.83 | -1.83 | 1.81 | 6.26 | 0.1593 | 0.8406 | 4.29 | 695,986.10 | -17.55 | -18.87 | -21.98 | -23.11 | 69.07 | 69.13 | -110.18 | -88.41 | 1.75 | -67.73 | 0.3065 | -- | 3.38 | 248.39 | 4.38 | -- | 8.36 | -- |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 9.35bn | 1.14bn | 27.35bn | 8.22k | 24.00 | 3.11 | -- | 2.93 | 0.7772 | 0.7772 | 6.34 | 5.99 | 0.4922 | 1.02 | 3.51 | 1,137,186.00 | 6.01 | 5.67 | 8.37 | 8.07 | 61.97 | 60.52 | 12.21 | 11.61 | 0.7919 | 6.25 | 0.4541 | 33.55 | 0.5199 | 10.28 | -28.88 | 50.51 | 7.21 | -- |
| Kangmei Pharmaceutical Co Ltd | 5.21bn | 255.55m | 28.01bn | 4.41k | 109.07 | 3.98 | -- | 5.37 | 0.0185 | 0.0185 | 0.3766 | 0.5079 | 0.3626 | 1.45 | 2.55 | 1,182,457.00 | 1.80 | -17.60 | 2.77 | -32.24 | 20.63 | -72.78 | 4.95 | -101.19 | 0.8398 | -- | 0.0346 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 8.92bn | 2.78bn | 28.33bn | 5.23k | 10.15 | 2.01 | -- | 3.18 | 3.03 | 3.03 | 9.71 | 15.27 | 0.5135 | 3.08 | 4.60 | 1,706,101.00 | 16.04 | 16.23 | 20.68 | 20.88 | 78.36 | 82.64 | 31.23 | 24.42 | 3.55 | -- | 0.1024 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
| Gan & Lee Pharmaceuticals | 2.95bn | 580.86m | 29.00bn | 4.48k | 49.37 | 2.59 | -- | 9.84 | 0.9773 | 0.9773 | 4.97 | 18.65 | 0.2558 | 0.8458 | 8.94 | 657,602.00 | 5.04 | 8.30 | 5.40 | 8.83 | 72.92 | 85.39 | 19.71 | 26.44 | 6.77 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
| Bluestar Adisseo Co | 14.95bn | 1.09bn | 30.98bn | 2.73k | 28.42 | 1.96 | -- | 2.07 | 0.4064 | 0.4064 | 5.57 | 5.90 | 0.6887 | 5.18 | 8.01 | 5,466,479.00 | 5.03 | 5.28 | 6.07 | 6.94 | 29.20 | 30.31 | 7.30 | 8.76 | 1.16 | 7.83 | 0.1105 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Xiamen Amoytop Biotech Co Ltd | 2.60bn | 740.69m | 31.68bn | 1.96k | 42.77 | 13.99 | -- | 12.21 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
| Humanwell Healthcare Group Co Ltd | 25.56bn | 1.96bn | 34.55bn | 17.68k | 17.47 | 1.93 | -- | 1.35 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
Data as of Nov 05 2024. Currency figures normalised to Gan & Lee Pharmaceuticals's reporting currency: Chinese Yuan Renminbi CNY
6.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 9.55m | 1.80% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 5.91m | 1.11% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2024 | 5.29m | 1.00% |
| Penghua Fund Management Co., Ltd.as of 30 Sep 2023 | 2.91m | 0.55% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2024 | 1.98m | 0.37% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 1.95m | 0.37% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 1.84m | 0.35% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2024 | 1.69m | 0.32% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 1.66m | 0.31% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.43m | 0.27% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
